PLoS ONE (Jan 2014)

In a safety net population HPV4 vaccine adherence worsens as BMI increases.

  • Diane M Harper,
  • Britney M Else,
  • Mitchell J Bartley,
  • Anne M Arey,
  • Angela L Barnett,
  • Beth E Rosemergey,
  • Christopher A Paynter,
  • Inge Verdenius,
  • Sean M Harper,
  • George D Harris,
  • Jennifer A Groner,
  • Gerard J Malnar,
  • Jeffrey Wall,
  • Aaron J Bonham

DOI
https://doi.org/10.1371/journal.pone.0103172
Journal volume & issue
Vol. 9, no. 7
p. e103172

Abstract

Read online

OBJECTIVES:Obesity adversely inhibits antibody response to vaccination. Three doses of HPV4 may or may not provide adequate long term protection against HPV 16/18 in obese females. The aim of this study was to determine whether adherence to HPV4 vaccination in a safety net population was reduced with increasing body mass index (BMI). METHODS:We designed a historical prospective study evaluating the number and dates of HPV4 dosing that occurred from July 1, 2006 through October 1, 2009 by the demographic characteristics of the 10-26 year old recipient females. The defined dosing intervals were adapted from the literature and obesity categories were defined by the WHO. RESULTS:1240 females with BMI measurements received at least one dose of HPV4; 38% were obese (class I, II and III) and 25% were overweight. Females with normal BMI received on-time triplet dosing significantly more often than did the obese class II and III females (30% vs. 18%, p<0.001). Obese class II/III females have a significant 45% less chance of completing the on-time triplet HPV4 series than normal women (OR = 0.55, 95% CI: 0.37, 0.83). Pregnancy history has a significant influence on BMI and HPV4 dosing compliance in this safety net population where 71% had been gravid. Hispanic females were less likely to complete HPV4 dosing regardless of BMI (aOR = 0.39, 95% CI: 0.16, 0.95). CONCLUSIONS:Obesity, as well as gravidity and Hispanic race, are risk factors for lack of HPV4 vaccine adherence among young females in a safety net population.